Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;123(3):1039-1047.
doi: 10.1007/s13760-023-02190-5. Epub 2023 Mar 3.

Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study

Simona Guerzoni  1 , Carlo Baraldi  2 , Daria Brovia  1 , Maria Michela Cainazzo  1 , Flavia Lo Castro  3 , Luca Pani  1   4   5   6
Affiliations

Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study

Simona Guerzoni et al. Acta Neurol Belg. 2023 Jun.

Erratum in

Abstract

Introduction: Migraine usually ameliorates after menopause. However, 10-29% of women still experience migraine attacks after menopause, especially if menopause is surgical. The use of monoclonal antibodies against the calcitonin gene-related peptide (CGRP) is changing the landscape of migraine treatment. This study aims to explore the effectiveness and safety of anti-CGRP monoclonal antibodies in women in menopause.

Methods: Women affected by either migraine or chronic migraine and treated with an anti-CGRP monoclonal antibody for up to 1 year. Visits were scheduled every 3 months.

Results: Women in menopause displayed a similar response compared to women of childbearing age. Among women in menopause, the women experiencing surgical menopause seemed to exhibit a similar response compared to the ones experiencing physiological menopause. Erenumab and galcanezumab displayed similar effectiveness in women in menopause. No serious adverse events were registered.

Discussion: The effectiveness of anti-CGRP monoclonal antibodies is almost the same between women in menopause and women of childbearing age, without appreciable differences between the different antibodies.

Keywords: Calcitonin gene-related peptide; Menopause; Migraine; Monoclonal antibodies.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202 - DOI
    1. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB (2010) Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 30:1065–1072. https://doi.org/10.1177/0333102409355601 - DOI - PubMed
    1. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A (2006) Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology 67:2154–2158. https://doi.org/10.1212/01.wnl.0000233888.18228.19 - DOI - PubMed
    1. Reddy N, Desai MN, Schoenbrunner A, Schneeberger S, Janis JE (2021) The complex relationship between estrogen and migraines: a scoping review. Syst Rev 10:72. https://doi.org/10.1186/s13643-021-01618-4 - DOI - PubMed - PMC
    1. Martin VT, Pavlovic J, Fanning KM, Buse DC, Reed ML, Lipton RB (2016) Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American migraine prevalence and prevention study. Headache 56:292–305. https://doi.org/10.1111/head.12763 - DOI - PubMed

Substances

LinkOut - more resources